Clinical Trials
14 trialsNCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
NCT02537613 2026-04-01
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06192888 2026-03-27
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04843904 2026-01-07
SAVE
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06916767 2025-11-10
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT05943496 2025-11-06
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT02992522 2025-09-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT06547944 2024-08-09
ZGR in TN CLL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Active not recruiting
NCT05894447 2024-04-12
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT03113695 2022-07-05
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
University of California, San Diego
Phase 1 Completed
NCT02877550 2022-06-10
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Swiss Cancer Institute
Phase 1 Completed
NCT02611908 2019-01-25
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
University of California, San Diego
Phase 1 Withdrawn